Low-level aviremic hepatitis C virus (HCV) RNA replication in the immune blood РBMСs/WBCs as one of the primary interferon-free DAA therapy outcomes in real clinical practice in antiviral therapy-naive patients with chronic HCV RNA viremia
DOI: https://doi.org/10.29296/25877305-2020-02-13
Issue:
2
Year:
2020
The paper presents the results of the authors’ own pilot study of the prevalence of secondary occult hepatitis C virus (HCV) infection after various primary interferon-free (direct-acting antivirals (DAA)) therapy regimens with original inhibitor drugs in real clinical practice. Examinations have been made in 27 patients randomly selected from 261 ones who achieved a traditional plasma sustained virological response at 12 weeks after the end of a DAA therapy cycle confirmed by HCV RNA aviremia.
Keywords:
гепатология
вторичная оккультная HCV-инфекция
вторичный оккультный гепатит С
безинтерфероновая DAA-терапия
иммунные клетки крови PBMC/WBC
периферические мононуклеары
хроническая виремия RNA HCV
репликация RNA HCV в PBMC/WBC
References:
- Ferri C., Ramos-Casals M., Zignego A.L. et al. International diagnostic guidelinesforpatients with HCV- expertstatement // Autoimmun. Rev. – 2016; 15 (12): 1145–60. DOI: 10.1016/j.autrev.2016.09.006
- McHutchinson J., Davis G., Esteban-Mur R. et al. Durability of sustainedviralresponse in patients with chronic hepatitis C aftertreatment with interferon alpha-2b aloneor in combination with ribavirin // Hepatology. – 2001; 34: 244.
- Shiratori Y., Imazeki F., Moriyama M. et al. Histologicimprovement of fibrosis in patients with hepatitis C whohavesustainedresponse to interferon therapy // Ann. Intern. Med. – 2000; 132: 517–24.
- Castillo I., Pardo M., Bartolomé J. et al. Occult Hepatitis C Virus Infection in Patients in Whom the Etiology of PersistentlyAbnormal Results of Liver-Function Tests Is Unknown // J. Infect. Dis. – 2004; 189 (1): 7–14.
- Attar V., VanThiel D. Review Article. A New Twist to a Chronic HCV Infection: Occult Hepatitis C // Gastroenterol. Res. Pract. – 2015; 2015: 579147. http://dx.doi.org/10.1155/2015/579147
- AbdAlla M., ElAwady M. Hepatitis C virus RNA strands detection in peripheral blood mononuclear cells legitimizes virus eradication in negative serumpcrnaive and post-treatment patients // J. Clin. Transl. Hepatol. – 2017; 5 (1): 1–8. DOI: 10.14218/JCTH.2016.00054
- Innes H., McDonald S., Hayes P. et al. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population // J. Hepatol. – 2017; 66 (1): 19–27. https://doi.org/10.1016/j.jhep.2016.08.004
- Yousif M., ElsadekFakhr A. et al. Prevalence of occult hepatitis C virus infection in patients who achieved sustained virologic response todirect-acting antiviral agents // Infez. Med. – 2018; 26 (3): 237–43.
- Mekky M., Sayed H., Abdelmalek M. et al. Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi centerstudy // Infect. Drug Resist. – 2019; 12: 273–9. DOI: 10.2147 / IDR.S181638
- Wróblewska A., Lorenc B., Cheba M. et al. Neutrocyte to lymphocyte ratiopredicts the presence of a replicative hepatitis C virus strand after therapy with direct acting antivirals // Clin. Exp. Med. – 2019; 19: 401–6. https://doi.org/10.1007/s10238-019-00561-y
- Lybecka C., Brenndörferc E., Sällbergc M. et al. Long-term follow-up aftercure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients // Eur. J. Gastroenterol. Hepatol. – 2019; 31 (4): 506–13. DOI: 10.1097/MEG.0000000000001316
- Znojko O.O., Lin'kova Ju.N., Morozova M.A. i dr. Klinicheskij opyt primenenija shemy trojnoj terapii, vkljuchajuschej tsepeginterferon al'fa-2b, simeprevir i ribavirin, u patsientov s hronicheskim gepatitom S genotipa 1 // Infektsionnye bolezni: novosti, mnenija, obuchenie. – 2016; 2 (15): 100–9 [Znoyko O.O., Lin’kova Yu.N., Morozova M.A. et al. Clinical practice of triple therapy with Cepeginterferon alfa-2b, simeprevir and ribavirin in patients with chronic hepatitis C virus genotype 1 infection // Infektsionnye bolezni: novosti, mneniya, obuchenie. – 2016; 2 (15): 100–9. (in Russ.)].
- Sulima D.L., Lioznov D.A., Jakovlev A.A. i dr. Pervyj v Rossii opyt primenenija GLE/PIB dlja lechenija HCV-infektsii genotipa 3a s krioglobulinemiej i soputstvujuschej HBV-infektsiej u patsienta s HBP S5d, lechennogo gemodializom i ozhidavshego transplantatsiju pochki // Vrach. – 2019; 30 (2): 3–13 [Sulima D., Lioznov D., Yakovlev A. et al. Russia’s first experience with GLE/PIB for the treatment of HCV infection genotype 3A with cryoglobulinemia and concomitant HBV infection in a hemodialysis patient with CKD S5d awaiting kidney transplantation // Vrach. – 2019; 30 (2): 3–13 (in Russ.)]. https://doi.org/10.29296/25877305-2019-02-01
- Sulima D.L., Sokolova O.I., Larionov V.A. i dr. Bezinterferonovaja DAA-terapija u patsientov s hronicheskoj HCV-infektsiej (novaja gipoteza na osnovanii 3-letnego prospektivnogo nabljudatel'nogo issledovanija dvuh klinik Sankt-Peterburga) // Sovremennaja meditsina. – 2019; 3 (15): 7–29 [Sulima D.L., Sokolova O.I., Larionov V.A. et al. Interferon-free DAA-therapy in patients with chronic HCV infection (new hypothesis based on a 3-year prospective observational study of two clinics in St. Petersburg) // Sovremennaya meditsina. – 2019; 3 (15): 7–29 (in Russ.)].
- Chomczynski P., Sacchi N. // Single-stepmethod of RNA isolation by acid guanidinium thiocyanate-phenol-chloroformextraction // Anal. Biochem. – 1987; 162 (1): 156–9.
- EASL Recommendations on Treatment of Hepatitis C 2015 // J. Hepatol. – 2015; 63: 199–236. DOI: 10.1016/j.jhep.2015.03.025
- EASL Recommendations on Treatment of Hepatitis C 2016 // J. Hepatol. – 2017; 66: 153–94. https://doi.org/10.1016/j.jhep.2016.09.001
- EASL Recommendations on Treatment of Hepatitis C 2018 // J. Hepatol. – 2018; 69: 461–511. https://doi.org/10.1016/j.jhep.2018.03.026
- Prihod'ko E.M., Seliverstov P.V., Adylov Sh.F. i dr. Vozmozhnosti regenerativnoj terapii v lechenii patsientov s hronicheskim gepatitom // Gastroenterologija Sankt-Peterburga. – 2018; 2: 91–2 [Prikhod’ko E.M., Seliverstov P.V., Adylov Sh.F. et al. Vozmozhnosti regenerativnoi terapii v lechenii patsientov s khronicheskim gepatitom // Gastroenterologiya Sankt-Peterburga. – 2018; 2: 91–2 (in Russ.)].